2025-04-15 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Analysis

**0) Introduction:** This report analyzes Colgate-Palmolive Co (CL), a leading global manufacturer and marketer of oral care, personal care, and home care products, based on the provided financial data.

**1) Performance vs. S&P 500 (VOO):**

Colgate-Palmolive's cumulative return of 27.96% significantly underperforms the S&P 500's return of 66.69% over the analyzed period.  The difference is -38.7%, placing it in the 36.1st percentile of the historical range of the divergence between CL and VOO (ranging from -64.8% to 7.4%).  This indicates CL's underperformance relative to the broader market.

The provided Alpha and Beta analysis shows mixed results:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 13.0% | 4.8% | -16.0% | 0.1 | 51.5 |
| 2016-2018  | -11.0% | 65.2% | -29.0% | 0.1 | 41.6 |
| 2017-2019  | 7.0% | 65.2% | -22.0% | 0.2 | 49.4 |
| 2018-2020  | 18.0% | 65.2% | -8.0% | 0.7 | 62.8 |
| 2019-2021  | 30.0% | 58.6% | -25.0% | 1.0 | 64.1 |
| 2020-2022  | 8.0% | 68.9% | 1.0% | 1.0 | 60.6 |
| 2021-2023  | 5.0% | 68.9% | -12.0% | 0.9 | 62.9 |
| 2022-2024  | 12.0% | 68.9% | -5.0% | 0.8 | 73.3 |
| 2023-2025  | 14.0% | 83.3% | 0.0% | 0.3 | 77.0 |

Note that the Alpha values are largely negative, suggesting underperformance relative to the market benchmark.  Beta values are generally below 1, indicating lower volatility than the market.  However, the interpretation of Alpha and Beta requires careful consideration of the specific time periods and market conditions. The provided MDD (Maximum Drawdown) figures highlight periods of significant losses.

**2) Recent Price Movement:**

* **Closing Price:** $94.98
* **5-Day Moving Average:** $91.92
* **20-Day Moving Average:** $91.83
* **60-Day Moving Average:** $90.25

The closing price is above all three moving averages, suggesting a recent upward trend.

**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4585 (High Risk category) suggests elevated market volatility.
* **RSI:** 62.46 (slightly above neutral; not overbought)
* **PPO:** 0.12 (positive, indicating bullish momentum)
* **20-Day Relative Divergence Change:** -14.9% (short-term bearish signal)
* **Expected Return:** -64.2% (This implies a significantly negative expected return compared to the S&P 500 over the long term. The negative expected return is exceptionally high and warrants further investigation into the model's assumptions and data used to generate this figure.)

The recent price change of $1.04 (from $94.0 to $94.98) indicates a slight upward movement, but not a dramatic surge.

**4) Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|----------------|
| 2024-10-25 | 0.9  | $5.03 B        |
| 2024-07-26 | 0.89 | $5.06 B        |
| 2024-04-26 | 0.83 | $5.07 B        |
| 2023-10-27 | 0.86 | $4.92 B        |
| 2024-10-25 | 0.86 | $4.92 B        | *(Duplicate entry, likely an error)*

EPS shows slight fluctuations, and revenue remains relatively stable around $5 Billion.  The duplicate entry needs clarification.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.95B | 60.30% |
| 2024-09-30 | $5.03B | 61.08% |
| 2024-06-30 | $5.06B | 60.62% |
| 2024-03-31 | $5.07B | 60.00% |
| 2023-12-31 | $4.95B | 59.60% |

Revenue is relatively stable, and profit margins are consistently high, around 60%.

**Capital and Profitability:**

| Quarter | Equity | ROE      |
|---------|---------|----------|
| 2024-12-31 | $0.21B | 348.58% |
| 2024-09-30 | $0.43B | 169.43% |
| 2024-06-30 | $0.12B | 594.31% |
| 2024-03-31 | $0.23B | 296.96% |
| 2023-12-31 | $0.61B | 117.90% |

Equity and ROE show significant fluctuations.  The extremely high ROE values in some quarters require further investigation to ensure data accuracy.

**6) Overall Conclusion:**

Colgate-Palmolive (CL) exhibits stable revenue and high profit margins. However, its performance significantly lags behind the S&P 500, indicated by a negative Alpha and a substantial underperformance in cumulative returns.  The high market risk indicator and the highly volatile ROE figures raise concerns.  The -64.2% expected return, if accurate, is extremely negative and suggests significant downside risk.  Further investigation is needed to validate the data, particularly the highly variable ROE and the extremely negative expected return, and to understand the reasons for the substantial underperformance relative to the market.  The provided data alone does not support a recommendation for long-term investment in CL.  Before making any investment decision, a thorough review of the company's financials, competitive landscape, and future prospects is recommended.
